Skip to content

JNDS, Volume 16, Number 1

Bianchi

University of North Texas Digital Library (University of North Texas) DOI: 10.17514/jnds-1997-16-1-p71-78 via OpenAlex

Summary

AI-generated from the abstract

Ketamine can produce experiences resembling near-death experiences (NDEs), but the nature of these experiences differs depending on the context—recreational use versus use in an operating room. Both ketamine and ibogaine, a substance used in Central African religious rituals to induce NDEs, are noncompetitive antagonists of the NMDA receptor. Ibogaine also elicits different experiences based on whether it is used in a hallucinatory context or in initiatic rituals that induce a superficial coma. These observations raise the question of whether the chemically-induced NDE-like experience stems from the specific substance or from the genuine comatose state itself.

Study at a glance

Characteristics Theoretical or philosophical paper Peer reviewed
Topics Ketamine
Keywords Nmda receptor Psychology Neuroscience Internal medicine
Key finding The context in which ketamine or ibogaine is used influences the nature of the near-death-like experience, suggesting that the experience may be related to the comatose state rather than the substance alone.

Abstract

Abstract: Although ketamine can induce a state similar to a near-death experience (NDE), there is a striking difference between experiences induced by ketamine used in a recreational context and in an operating room. Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate receptor, as is ibogaine, the main alkaloid of a shrub used in Central Africa to induce NDEs in a religious context. Ibogaine can also elicit different experiences when used in a hallucinatory context or in initiatic rituals, where a superficial state of coma is induced. These data raise the question of whether the chemically-induced NDE-like experience is related to the use of a particular kind of substance or to a genuine comatose state.

Explore topics

Comments

No comments yet.

Log in to comment